Wat it nijste kankerûndersyk werklik oantoant
June 6, 2026 · Frisian News
Major cancer studies from 2025 and early 2026 show mixed results that contradict the optimism of press releases. Simple lifestyle changes still outperform expensive new drugs for most patients.
FryskIn ûndersyksstifting publisearre dit jier gegevens wêrút bliek dat in nij immunoterapy-middel de oerlibbing ferlingde by pasjinten mei longkanker yn stadium fjouwer. It perskommunikee neamde it in trochbraak. Wat net neamd waard: it ûndersyk rûn jierren tsjin hege kosten, omfette in beperkt tal pasjinten en gie gear mei wichtige neiwurkingen by in substansjeel diel fan de groep. Njonken dit resultaat fûn in grut ûndersyk dat it stopjen mei roken, gewichtsferlis en minder alkoholgebrûk it kankerrisiko substansjeel ferleege. Dat ûndersyk koste folle minder en brûkte gjin medisinen.
Farmaseütyske bedriuwen finansiere it measte kankerûndersyk yn wolfearrende lannen. Dit makket in ynboude foarkar foar medisinoplossingen. Ûndersyk hat oantoand dat artikelen finansierd troch medisinmakkers signifikant faker ta positive konklúzjes komme as artikelen finansierd troch folkssûnensburo's. Itselde patroan jildt yn Europa. As jo it jild folgje, sjogge jo wêrom't djoere rjochte terapyen grutte krântekoppen krije wylst saaie previnsjeûndersiken yn it stof lizzen bliuwe.
De echte winsten yn kankeroerlibbing kamen fan iere opsporing en sjirurgy, net fan de nijste medisinen. Sjoernalisten skriuwe net oer mammogramen en kolonoskopyen. Redakteuren publisearje ferhalen oer wûndermiddels.
Guon nije medisinen helpe spesifike pasjintgroepen echt. CAR-T-seltherapy wurket echt foar bepaalde bloedkankers en rêdt libben dy't oars ferlern gean soenen. Mar dizze winsten binne beperkt. In pasjint mei kanker fan de alvleisklier of avansearre aaistokkanker sil net baat hawwe by de measte oare resinte medisinen. De kanker mutearre om it medisyn hinne. Artsen witte dit. De perskommunikees sizze it net.
De kleau tusken wat ûndersyk werklik oantoant en wat pasjinten hearre, wurdt hieltyd grutter. Djoere kombinaasjeterapyen mei meardere goedkarde medisinen wurde oanpriizge as nije oanpakken. In ienfâldige fraach dy't nimmen yn de krântekoppen stelt: is dit wêr't wy ûndersyksjild oan besteegje moatte?
A research foundation released data this year showing that a new immunotherapy drug extended survival in stage four lung cancer patients. The press release called it a breakthrough. What it did not mention: the study ran for years at great expense, enrolled a limited number of patients, and came with significant side effects in a substantial portion of the group. Side by side with this result, a large study found that quitting smoking, losing weight, and drinking less alcohol reduced cancer risk substantially. That study cost far less and involved no drugs.
Pharmaceutical companies fund most cancer research in wealthy countries. This creates a built-in bias toward drug solutions. Research has shown that papers funded by drug makers are significantly more likely to reach positive conclusions than papers funded by public health agencies. The same pattern holds in Europe. When you follow the money, you see why expensive targeted therapies get headlines while boring prevention studies gather dust.
The real gains in cancer survival have come from early detection and surgery, not from the newest medications. Journalists do not write about mammograms and colonoscopies. Editors run stories about miracle pills instead.
Some new drugs do help specific patient groups. CAR-T cell therapy genuinely works for certain blood cancers, saving lives that would otherwise have been lost. But these wins are narrow. A patient with pancreatic cancer or late-stage ovarian cancer will not benefit from most other recent drugs. The cancer simply mutates around the medicine. Doctors know this. The press releases do not say it.
The gap between what research actually shows and what patients hear keeps growing. High-cost combination therapies using multiple approved drugs have been marketed as new approaches. A simple question nobody asks in the headlines: is this what we should be spending research money on?
Published June 6, 2026 · Frisian News · Ljouwert, Fryslân